Predictive Modeling of Hypoglycemia Risk with Basal Insulin Use in Type 2 Diabetes: Use of Machine Learning in the
Zsolt Bosnyak1, Fang Liz Zhou2, Javier Jimenez2
1Sanofi, Paris, France. Zsolt.Bosnyak@sanofi.com.
Introduction:
Hypoglycemia remains a global burden and a limiting factor in the glycemic management of people with diabetes using basal insulins or oral antihyperglycemic drugs. Hypoglycemia data gleaned from randomized controlled trials (RCTs) have limited generalizability, as the strict RCT methodology and inclusion criteria do not fully reflect the real-world clinical picture. Therefore, real-world evidence, gathered from sources including electronic health records (EHR), is increasingly recognized as an important adjunct to RCTs.
Aims And Methods:
The LIGHTNING study applied advanced analytical methods, including machine learning (ML), to EHR data. The study aimed to predict hypoglycemic event rates in patients with type 2 diabetes (T2DM) receiving different basal insulin treatments to identify potential subgroups of patients who are at lower risk of hypoglycemia when treated with one basal insulin compared with another and to predict hypoglycemia-related cost savings in these subgroups. Here we provide an overview of the objectives, study design and methods, and validation approaches used in the LIGHTNING study.
Conclusion:
It is hoped that results of the LIGHTNING study will help facilitate real-world clinical decision-making in addition to providing a clinically relevant predictive model of hypoglycemia risk.
Funding:
Sanofi.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Type IV Collagen of Basal Lamina
A type IV collagen molecule has six alpha chains which can...
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Hypoglycemia and Glucagon
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...


